Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Bacac

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Blood|March 4, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Thomas Hofer, Christine Kuettel, et al.
Nature Communications|October 31, 2024
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaRebekka Wegmann, Ximena Bonilla, Ruben Casanova, et al.
Cancer Cell|January 22, 2021
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision supportAnja Irmisch, Ximena Bonilla, Stéphane Chevrier, et al.
Nature Medicine|May 27, 2025
Feasibility of multiomics tumor profiling for guiding treatment of melanomaNicola Miglino, Nora C Toussaint, Alexander Ring, et al.
Nature Communications|July 13, 2026
A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategyFrancis Jacob, Rebekka Wegmann, Joanna Ficek-Pascual, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Blood|March 4, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Thomas Hofer, Christine Kuettel, et al.
Nature Communications|October 31, 2024
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaRebekka Wegmann, Ximena Bonilla, Ruben Casanova, et al.
Cancer Cell|January 22, 2021
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision supportAnja Irmisch, Ximena Bonilla, Stéphane Chevrier, et al.
Nature Medicine|May 27, 2025
Feasibility of multiomics tumor profiling for guiding treatment of melanomaNicola Miglino, Nora C Toussaint, Alexander Ring, et al.
Nature Communications|July 13, 2026
A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategyFrancis Jacob, Rebekka Wegmann, Joanna Ficek-Pascual, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 8